Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Source Summary

Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD) Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol...